[1] Kim J, Harper A, Mccormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med, 2025; 31, 1154−62. doi:  10.1038/s41591-025-03502-3
[2] Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics, 2023; 15, 1796. doi:  10.3390/pharmaceutics15071796
[3] Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ, 2023; 381, e071674. doi:  10.1136/bmj-2022-071674
[4] Agostinetto E, Losurdo A, Nader-Marta G, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs, 2022; 31, 567−91. doi:  10.1080/13543784.2022.2049232
[5] Yang RN, Li YY, Wang H, et al. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed, 2022; 3, 8. doi:  10.1186/s43556-022-00071-6
[6] Albergaria A, Ricardo S, Milanezi F, et al. Nottingham prognostic index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer, 2011; 11, 299.
[7] Li YX, Xiong J, Hu ZQ, et al. Denoised recurrence label-based deep learning for prediction of postoperative recurrence risk and sorafenib response in HCC. BMC Med, 2025; 23, 162. doi:  10.1186/s12916-025-03977-4
[8] Zhang YB, Yang ZJ, Chen RQ, et al. Histopathology images-based deep learning prediction of prognosis and therapeutic response in small cell lung cancer. npj Digit Med, 2024; 7, 15. doi:  10.1038/s41746-024-01003-0
[9] Fremond S, Andani S, Barkey Wolf J, et al. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the portec randomised trials and clinical cohorts. Lancet Digit Health, 2023; 5, e71−82. doi:  10.1016/S2589-7500(22)00210-2
[10] Saillard C, Schmauch B, Laifa O, et al. Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides. Hepatology, 2020; 72, 2000−13. doi:  10.1002/hep.31207
[11] Nazir, S. , Dickson, D. M. , & Akram, M. U. Survey of explainable artificial intelligence techniques for biomedical imaging with deep neural networks. Comput Biol Med, 2023; 156, 106668.
[12] Occhipinti A, Verma S, Doan LMT, et al. Mechanism-aware and multimodal AI: beyond model-agnostic interpretation. Trends Cell Biol, 2024; 34, 85−9. doi:  10.1016/j.tcb.2023.11.002
[13] Zhang YQ, Wang YC, Chen JX, et al. Enhancing short-term algal bloom forecasting through an anti-mimicking hybrid deep learning method. J Environ Manage, 2025; 379, 124832. doi:  10.1016/j.jenvman.2025.124832
[14] Salih A, Galazzo IB, Gkontra P, et al. Explainable artificial intelligence and cardiac imaging: toward more interpretable models. Circ Cardiovasc Imaging, 2023; 16, e014519. doi:  10.1161/circimaging.122.014519
[15] Lekadir K, Frangi AF, Porras AR, et al. Future-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ, 2025; 388, e081554. doi:  10.1136/bmj-2024-081554
[16] Chen HM, Gomez C, Huang CM, et al. Explainable medical imaging AI needs human-centered design: guidelines and evidence from a systematic review. npj Digit Med, 2022; 5, 156. doi:  10.1038/s41746-022-00699-2
[17] Zhang HJ, Ogasawara K. Grad-CAM-based explainable artificial intelligence related to medical text processing. Bioengineering, 2023; 10, 1070. doi:  10.3390/bioengineering10091070
[18] Schuettfort VM, Pradere B, Rink M, et al. Pathomics in urology. Curr Opin Urol, 2020; 30, 823−31. doi:  10.1097/MOU.0000000000000813
[19] Lin H, Hua JJ, Gong ZZ, et al. Multimodal radiopathological integration for prognosis and prediction of adjuvant chemotherapy benefit in resectable lung adenocarcinoma: a multicentre study. Cancer Lett, 2025; 616, 217557. doi:  10.1016/j.canlet.2025.217557
[20] Brancato V, Garbino N, Aiello M, et al. Exploratory analysis of radiomics and pathomics in uterine corpus endometrial carcinoma. Sci Rep, 2024; 14, 30727. doi:  10.1038/s41598-024-78987-y
[21] Verdicchio M, Brancato V, Cavaliere C, et al. A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images. Heliyon, 2023; 9, e14371. doi:  10.1016/j.heliyon.2023.e14371
[22] Graham S, Vu QD, Raza SEA, et al. Hover-net: simultaneous segmentation and classification of nuclei in multi-tissue histology images. Med Image Anal, 2019; 58, 101563. doi:  10.1016/j.media.2019.101563
[23] Liu XY, Yuan P, Li RL, et al. Predicting breast cancer recurrence and metastasis risk by integrating color and texture features of histopathological images and machine learning technologies. Comput Biol Med, 2022; 146, 105569. doi:  10.1016/j.compbiomed.2022.105569
[24] Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol, 2022; 19, 91−113. doi:  10.1038/s41571-021-00565-2
[25] Swanson K, Wu E, Zhang A, et al. From patterns to patients: advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell, 2023; 186, 1772−91. doi:  10.1016/j.cell.2023.01.035
[26] Wang K, Xu JJ, Zhang T, et al. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: a meta-analysis. Oncotarget, 2016; 7, 44288−98. doi:  10.18632/oncotarget.9988
[27] Leon-Ferre RA, Jonas SF, Salgado R, et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA, 2024; 331, 1135−44. doi:  10.1001/jama.2024.3056
[28] Mao Y, Qu Q, Zhang YZ, et al. The value of tumor infiltrating lymphocytes (tils) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One, 2014; 9, e115103. doi:  10.1371/journal.pone.0115103
[29] de Melo Gagliato D, Cortes J, Curigliano G, et al. Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice. Biochim Biophys Acta Rev Cancer, 2017; 1868, 527−37. doi:  10.1016/j.bbcan.2017.10.003
[30] Helal C, Djerroudi L, Ramtohul T, et al. Clinico-pathological factors predicting pathological response in early triple-negative breast cancer. npj Breast Cancer, 2025; 11, 15. doi:  10.1038/s41523-025-00729-8
[31] Gao GX, Wang ZH, Qu X, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer, 2020; 20, 179. doi:  10.1186/s12885-020-6668-z
[32] Deepak KGK, Vempati R, Nagaraju GP, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res, 2020; 153, 104683. doi:  10.1016/j.phrs.2020.104683
[33] Guo J, Sun X, Pan GW, et al. Pan-cancer immunogenic death analysis identifies key roles of CXCR3 and CCL18 in hepatocellular carcinoma. Genes Dis, 2024; 11, 568−70. doi:  10.1016/j.gendis.2023.04.007
[34] Sui X, Chen CX, Zhou XM, et al. Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma. J Exp Clin Cancer Res, 2023; 42, 51. doi:  10.1186/s13046-023-02612-5
[35] Hao M, Huang B, Wu RF, et al. The interaction between macrophages and triple-negative breast cancer cells induces ROS-mediated interleukin 1α expression to enhance tumorigenesis and metastasis. Adv Sci, 2023; 10, 2302857. doi:  10.1002/advs.202302857
[36] Zhuang MY, Zhang XQ, Ji J, et al. Exosomal circ-0100519 promotes breast cancer progression via inducing M2 macrophage polarisation by USP7/NRF2 axis. Clin Transl Med, 2024; 14, e1763. doi:  10.1002/ctm2.1763
[37] Franken A, Bila M, Mechels A, et al. CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity, 2024; 57, 541-58. e7.
[38] Yu KH, Zhang C, Berry GJ, et al. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun, 2016; 7, 12474. doi:  10.1038/ncomms12474
[39] Chen DX, Fu MT, Chi LJ, et al. Prognostic and predictive value of a pathomics signature in gastric cancer. Nat Commun, 2022; 13, 6903. doi:  10.1038/s41467-022-34703-w
[40] Zhang J, Wu ZR, Zhao J, et al. Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. Eur Radiol, 2021; 31, 3661−72. doi:  10.1007/s00330-020-07524-y
[41] Xie N, Zhang LC, Fu BM, et al. Effect of different concentrations of GM-CSF on biological behavior of dendritic cells cultured in vitro. World Chin J Digestol, 2016; 24, 2038−44. (In Chinese) doi:  10.11569/wcjd.v24.i13.2038
[42] Ma D, Dai LJ, Wu XR, et al. Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell, 2025; 43, 1061-75. e7.
[43] Liu Y, Liu S, Wang WD, et al. Determination of volume change of LPS-stimulated mouse peritoneal macrophages by flow cytometry. Basic Clin Med, 2014; 34, 767−70. (In Chinese)
[44] Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology, 2005; 69, 4−10. doi:  10.1159/000088478
[45] Sharma P, Chida K, Wu RR, et al. VEGFA gene expression in breast cancer is associated with worse prognosis, but better response to chemotherapy and immunotherapy. World J Oncol, 2025; 16, 120−30. doi:  10.14740/wjon1993
[46] Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 2009; 100, 1385−92. doi:  10.1038/sj.bjc.6605017
[47] Liu G, Chen XT, Zhang H, et al. Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients. Front Oncol, 2022; 12, 1019247. doi:  10.3389/fonc.2022.1019247
[48] Dong F, Ruan SN, Wang JL, et al. M2 macrophage-induced LncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of vegfr2. Cell Death Dis, 2020; 11, 728. doi:  10.1038/s41419-020-02926-8
[49] Luan H, Jian LG, Huang YY, et al. Identification of novel therapeutic target and prognostic biomarker in matrix metalloproteinase gene family in pancreatic cancer. Sci Rep, 2023; 13, 17211. doi:  10.1038/s41598-023-44506-8
[50] Liu ZK, Hu SY, Zhao XL, et al. AKAP12 positive fibroblast determines immunosuppressive contexture and immunotherapy response in patients with TNBC by promoting macrophage M2 polarization. J Immunother Cancer, 2024; 12, e009877. doi:  10.1136/jitc-2024-009877
[51] Kondo T. [Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis]. Brain Nerve, 2009; 61, 741−51.